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To tbe Editor:
The elegant experiments of Cadroy et al.' have incited
an editorial by Lane and Ryan' that concludes that
anti-factor Xa activity seems a better yardstick of the
heparin effect than antithrombin action is. This is in
apparent contradiction to recent workt (and references
therein) that shows that in clotting plasma with heparin,
(1) the anti-Ila action is the main cause of the diminution
of active thrombin and (2) the free factor Xa levels can be
inhibited over 600/o without inhibition of prothrombin
activation. This itself is in accordance with observations
(cited in Cadroy et al.t) showing that inhibition of factor
Xa activity (pentasaccharide) has a poor antithrombotic
effect compared with inhibition of thrombin activity
(hirudin, dermatan sulfate).
The contradiction probably arises from the fact that the
anti-factor Xa and the anti-factor IIa activities as given by
Cadroy et al. bear no direct relationship to the activities of
their samples. The anti-factor Xa values have been
obtained with bovine factor Xa in the absence of Ca* *,
whereas the relevant data are on primate factor Xa in the
presence of Ca*' .  The anti- factor I Ia values given are
measured by clotting tests that are either not specific
(activated partial thromboplastin time [APTT]) or are
notoriously imprecise (thrombin clotting time [TCT]).
'We determined the increase, per microgram of heparin
per milliliter, of the decay constant of endogenous human
thrombin and factor Xa in human plasma. We also
determined what part of the heparin would be bound to
antithrombin III (ATIII) and what amount would be
neutralized due to platelet factor a (pfa) that is released
in clotting platelet-rich plasma from thrombin-activated
platelets.lo With these data we calculated what the effect
of the heparin concentration that causes 507o inhibition
of thrombus formation (IC50) from Cadroy's experi-
ments would be in clotting human platelet-rich plasma
in terms of (1) available AIIII binding material, (2) the
breakdown constant of factor IIa, and (3) the break-
down constant of factor Xa. The results are presented
in Table I.
The argument of Lane and Ryan2 is essentially that the
ratio of unfractionated heparin (UFH) activity to low
molecular weight heparin (CY222) activity is near unity
when the concentrations are expressed in anti-Xa units,
but not otherwise. When calculated on the basis of exact
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UFH, Unfractionated heparin; CY222, low molecular weight heparin; pf4,
platelet factor 4, ATlll, a tilftombrn lll, hep, heparin
data obtained in human plasma-which might be a better
approximation to what must have happened in the
baboons-the choice between the possible modes of
expressing the activity becomes much less obvious.
Prof. H. C. Hemker
Department of Biochemistry
Biomedical Centre
Rij lcsuniv ers iteit Limburg
Postbus 616
6200 MD Maasticht
The Netherlands
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